Fig. 7

Exosomal circCCAR1 is increased in HCC patients. A Transmission electron microscopy detected the exosomes. B NanoSight particle tracking analysis of the size distributions and number of exosomes. C The levels of exosome markers (CD63 and TSG101) in purified exosomes. D The level of circCCAR1 in exosomes from the serum of HCC patients and healthy donors. ***p < 0.001. E The correlation between exosomal circCCAR1 in serum and circCCAR1 in tumor samples was assessed by Spearman correlation analysis. F The association of exosomal circCCAR1 levels and overall survival in HCC patients. G The level of circCCAR1 in exosomes in culture medium from LO2 cells and HCC cells. ***p < 0.001 vs. LO2. H-I The level of circCCAR1 in HCC cells or exosomes isolated from the supernatants of HCC cells treated with GW4869. ***p < 0.001 vs. DMSO. J The level of circCCAR1 in exosomes in HCC cells after circCCAR1 overexpression or depletion. ***p < 0.001 vs. vector; ###p < 0.001 vs. sh-NC. K The binding of circCCAR1 and hnRNPA2B1 was confirmed by RIP assay. ***p < 0.001 vs. IgG. L The binding of circCCAR1 and hnRNPA2B1 was confirmed by RNA pulldown assay. M The relative circCCAR1 expression in HCC cells after hnRNPA2B1 knockdown. N The relative circCCAR1 expression in exosomes after hnRNPA2B1 knockdown. ***p < 0.001 vs. sh-NC